HRAS and cancer: In addition, class 3 BRAF mutations were more prevalent in HRAS-mutant salivary gland (5%), and bladder (9%), and melanoma (11%) cancers, whereas none were present in the respective KRAS- and NRAS-mutant tumors (p<0.05 for all).